Uncontrolled Central Nervous System (CNS) metastasis.

Previous exposure to monoclonal antibodies, signal transduction inhibitors or Epidermal growth factor receptor (EGFR) targeting therapy

Concurrent malignancy

Prior chemotherapy for NSCLC

Pre-existing ascites grade ≥ 2 or pericardial effusion grade ≥ 2

Superior vena cava syndrome contra-indicating hydration

White Blood Cells (WBC) \< 3,000/mm³

Absolute neutrophile count (ANC) \< 1,500/mm³

Platelet \< 100,000/mm³

Hemoglobin (Hgb) \< 9.0 g/dL

Total bilirubin \> 1.5 x Upper limit of normal (ULN).

Aspartate aminotransferase (AST) or Alanine-aminotransferase (ALT) \> 5.0 x ULN.

Serum creatinine \>1.25 x ULN and calculated creatinine clearance \<60mL/min

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer